BMO Capital Markets analyst M. IanSomaiya and team take a look at the “clinical readouts through the end of 2016″ and find upside catalysts for Celgene (CELG), Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) They explain:
Paulo Fridman/Bloomberg News
Celgene: We believe positive data from the mongersen Phase 2 endoscopy study should move shares higher if the trial demonstrates a benefit on CDAI (the Phase 3 primary endpoint) in line with the IGON-1 Phase 2 trial and endoscopic improvement correlated with therapy duration.
Amgen: We believe positive data from the GLAGOV vascular imaging trial could provide a positive read-through to the success of the ongoing FOURIER CV outcomes trial (data expected 2017).
Biogen: We believe positive titration data from the ongoing Phase 1b study of aducanumab in Alzheimer’s disease could de-risk the ongoing Phase 3 trials.
gold investment: Nature's Sunshine Products, Inc.(NATR)
Advisors’ Opinion:
- [By Lisa Levin]
Non-cyclical consumer goods & services sector was the top gainer in the US market on Tuesday. Top gainers in the sector included Nature's Sunshine Prod. (NASDAQ: NATR), Bridgford Foods Corporation (NASDAQ: BRID), and SunOpta, Inc. (USA) (NASDAQ: STKL).
gold investment: CME Group Inc.(CME)
Advisors’ Opinion:
- [By ]
Market Exchanges like the CME Group (Nasdaq: CME) have just started allowing trading in bitcoin futures and could attract an entirely new type of retail user as well as allowing institutional clients access to the bitcoin theme. Exchanges make their money on transactional volume, so a bursting of the bitcoin bubble wouldn’t necessarily mean weakness for shares.
- [By David Zeiler]
Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.
gold investment: AbbVie Inc.(ABBV)
Advisors’ Opinion:
- [By J.B. Maverick]
The pharmaceutical and health care sectors are generally less vulnerable to volatile and cyclical market moves, and may be one of the safer bets in 2016. Major drug manufacturer AbbVie, Inc. (NYSE: ABBV) has performed well for investors, and there are plenty of reasons to believe it will continue to do so. It is difficult to find a stock that shows a return on equity (ROE) of 59.3%, more than double the industry average of 23.3%. In addition, the stock’s dividend yield of 3.76% is well above the S&P 500 average, and the company has stated its firm commitment to return income to investors with a growing dividend payout. With successful drugs such as Humira and Imbruvica, and promising new ones in the company’s development pipeline, AbbVie has experienced revenue growth from $14 billion to $23 billion since 2009, and analysts project earnings per share (EPS) in the neighborhood of $5 for 2016, which represents an increase of 17%.
- [By WWW.MONEYSHOW.COM]
AbbVie (ABBV) reported third quarter 2016 net sales increased a healthy 8% to $6.4 billion with net income increasing 29% to $1.6 billion and EPS increasing 31% to $.97.
- [By Keith Speights, Brian Stoffel, and George Budwell]
Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.
- [By Jim Robertson]
That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:
From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth. From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.
Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl
gold investment: Lifetime Brands Inc.(LCUT)
Advisors’ Opinion:
- [By Lisa Levin]
On Monday, cyclical consumer goods & services shares gained by 0.41 percent. Top gainers in the sector included Kandi Technologies Group Inc (NASDAQ: KNDI), Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT), and Lifetime Brands Inc (NASDAQ: LCUT).
gold investment: Immunomedics, Inc.(IMMU)
Advisors’ Opinion:
- [By Chris Lange]
Immunomedics, Inc. (NASDAQ: IMMU) saw its shares rise after the firm sent out a letter to shareholders imploring them to vote for its director nominees at the upcoming annual stockholders meeting on February 16. The board of directors is making this request because it is currently waging a proxy contest with venBio SelectAdvisor.
gold investment: China Petroleum & Chemical Corporation(SNP)
Advisors’ Opinion:
- [By Paul Ausick]
The Permian Basin pipeline project includes an investment by China’s state-controlled China Petroleum & Chemical Corp. (NYSE: SNP), aka Sinopec. Other partners in the project include ArcLight Capital and Freepoint Commodities LLC. The deal also includes an expansion to oil storage facilities in the U.S. Virgin Islands, where recent hurricanes have caused so much damage. The project still requires approval from both countries governments.’
